We have observed that patients with PV/ET presenting with SVT have a lower JAK2 allele burden and a lower number of pathogenic mutations than matched MPN patients without SVT of the same age, sex, and diagnosis. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.